Ibuprofen Kabi

Ibuprofen, the active ingredient in Ibuprofen Kabi, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an intravenous solution for intravenous use. It treats mild to moderate pain, fever, inflammation, and post‑operative pain in adult patients.\n\nGNH India supplies Ibuprofen Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibuprofen Kabi belongs to the NSAID class and acts on inflammatory pathways to relieve symptoms.\n\nMild to moderate pain: provides analgesia for surgical and non‑surgical pain.\nFever: reduces elevated body temperature.\nInflammation: decreases swelling associated with musculoskeletal conditions.\nPost‑operative pain: controls pain after surgery.

Adverse reactions may occur with any NSAID therapy.\n\nCommon Side Effects:\n- Nausea or dyspepsia\n- Headache or dizziness\n- Injection‑site discomfort\n- Transient elevation of liver enzymes\n- Mild renal function changes\n\nSerious or Rare Side Effects:\n- Gastrointestinal bleeding or ulceration\n- Acute renal failure or worsening chronic kidney disease\n- Severe hypersensitivity reactions including anaphylaxis\n- Stevens‑Johnson syndrome or toxic epidermal necrolysis\n- Cardiovascular thrombotic events such as myocardial infarction or stroke

Use of Ibuprofen Kabi requires careful assessment of patient risk factors.\n\nAssess renal function: avoid in severe renal impairment.\nMonitor for gastrointestinal bleeding: use with caution in patients with ulcer disease.\nUse caution in cardiovascular disease: consider increased thrombotic risk.\nAvoid in known hypersensitivity to ibuprofen or other NSAIDs.\nPregnancy and lactation: consult obstetrician, limited safety data.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ibuprofen Kabi can interact with several drug classes, requiring clinical vigilance.\n\nMajor Interactions (Avoid):\n- Anticoagulants (e.g., warfarin): increased risk of bleeding.\n- Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity.\n- ACE inhibitors in volume‑depleted patients: heightened risk of renal failure.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: possible alterations in renal function.\n- Methotrexate: reduced clearance leading to toxicity.